Stay updated on Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed from the Record History.SummaryDifference0.1%

- Check24 days agoChange DetectedRevision: v3.4.3 has been added and Revision: v3.4.2 has been removed from the history.SummaryDifference0.1%

- Check52 days agoChange DetectedA new site revision (v3.4.2) was added and a prior funding notice (v3.4.1) removed; these administrative changes do not affect the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check59 days agoChange DetectedA new government funding notice about the NIH Clinical Center operating status has been added. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.6%

- Check66 days agoChange DetectedShow glossary option and color-coding explanations have been added to the study history page, clarifying how additions (green) and deletions (red) are displayed. The revision label updated to v3.4.0 and the 'No FEAR Act data' wording was removed in favor of the current phrasing. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check81 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; no changes to study data or major content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.